Pharmafile Logo

ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment

January 27, 2026 | HEOR, Market Access, RWE, Top Trends, ispor, organization 

In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on our ability to influence decisions under constraint.

- PMLiVE

Read ISPOR’s Top 10 HEOR Trends for 2026-2027 in isolation, and nothing seems radical. But as a system, the message is unmistakable. We have hit a structural inflection point in this industry.

For years, the mandate for HEOR organizations was simple: generate evidence.

Today, that mandate has shifted. We are no longer being evaluated on our ability to produce data; we are being judged on our ability to influence decisions under constraint. That requires adaptable teams, cross-functional perspectives, and the ability to evolve strategy in real-time.

The central question for leadership is no longer, “Can we generate the data?” That problem is largely solved. The question now is, “What evidence will have the most impact on decision-making?”

The selection problem

We are drowning in the data lakes. The explosion of AI and Real-World Evidence (RWE) means we can run almost any analysis we can dream up. But just because we can analyze everything doesn’t mean we should.

Abundance is becoming our biggest liability. Organizations that analyze everything will lose to those that curate. The advantage lies in distinguishing what is technically interesting from what is defensible under scrutiny. Many strategies quietly fail right here, mistaking volume for insight…

Read more

This content was provided by Genesis Research Group

Company Details

 Latest Content from  Genesis Research Group 

Fit-for-purpose matchmaking webinar: a data selection and RWE approach for both regulatory and HTA audiences

This webinar reviews considerations for the design and data selection for RWE studies, including external control arm studies, to meet regulatory and HTA needs. Regulators and agencies responsible for market...

Genesis Research Group RWD / HTA / regulatory / ECA webinar on 15 Feb: reserve your place!

On 15 February 2024, Carole Longson and Allie Sosinsky of Genesis Research Group, a leading global provider of tech-enabled real-world evidence, market access, and HEOR solutions, will present a webinar...

Genesis Research Insights & Evidence webinar 20 Oct: Reserve your place!

Join Priti Jhingran of Genesis Research and Tijana Ignjatovic of Market Access Transformation (MAT) for their webinar 'Accelerating the Generation of Payer Insights and Evidence Across the Product Lifecycle to...

Leading pharmaceutical executive Jennifer Fillman joins evidence-based solution provider Genesis Research as Chief Financial Officer

International health economics and outcomes research (HEOR) and real-world evidence (RWE) organization Genesis Research has announced the appointment of Jennifer Fillman as its new Chief Financial Officer. Prior to joining...

Genesis Research and Syapse combine forces to offer RWE and data to oncology innovators

Genesis Research is delighted to announce a strategic partnership with Syapse®, combining the expertise and resources of both companies to better serve clients that are developing new oncology innovations.